PubMed20 Apr 2026Diabetes care● 5/10i Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams.
Alexopoulos AS, Cusi K
Even light-to-moderate alcohol intake accelerates MASLD progression to cirrhosis and hepatocellular carcinoma in people with diabetes and obesity, with the new MetALD category showing higher all-cause mortality than MASLD alone. Clinical practice review examining the 2023 nomenclature revision and integration of alcohol assessment tools like AUDIT questionnaire into diabetes/obesity care pathways. This establishes alcohol screening as standard practice in metabolic liver disease management, expanding the patient population requiring liver monitoring beyond traditional heavy drinkers. GLP-1 receptor agonists show emerging evidence for reducing alcohol consumption alongside their established metabolic benefits.
Strategic Signal
The MetALD designation creates a broader patient population requiring liver monitoring in diabetes and obesity care, potentially expanding the addressable market for MASLD treatments. GLP-1 receptor agonists gain additional differentiation through emerging alcohol reduction benefits, strengthening their position with endocrinologists managing complex metabolic patients. This clinical pathway integration supports broader GLP-1 utilization arguments for US payers and European HTA bodies evaluating comprehensive metabolic care coverage.
GLP-1Type 2 diabetesWeight lossLiver/NASH
Original Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects the majority of individuals with diabetes and severe obesity, and is one of the most common indications for liver transplantation in the U.S. Emerging evidence underscores the synergistic and detrimental impact of alcohol and metabolic disease on liver and overall health. In 2023, the nomenclature for steatotic liver disease was revised to include a new subcategory known as MetALD (metabolic dysfunction- and alcohol-associated liver disease), which acknowledges alcohol use as a cofactor in liver injury alongside metabolic risk factors. This review offers key insights into the role of alcohol use as both a direct hepatotoxin and an indirect contributor to insulin resistance, dyslipidemia, and obesity. Notably, even light-to-moderate alcohol intake may hasten MASLD progression to cirrhosis and hepatocellular carcinoma, especially in individuals with existing metabolic disease, and can worsen cardiovascular disease risk. MetALD is associated with increased all-cause, cancer-related, and liver-related mortality in comparison with MASLD, reinforcing the importance of accurate alcohol assessment in managing diabetes and obesity. Diagnosis now requires stratifying alcohol use and integrating tools such as the Alcohol Use Disorders Identification Test (AUDIT) questionnaire and phosphatidylethanol testing. The caveats and use of these tools in clinical practice are discussed. Management strategies for MASLD focus on lifestyle changes, weight loss, and medications such as glucagon-like peptide 1 receptor agonists, with emerging evidence suggesting that these agents may also reduce alcohol consumption. However, treatment data on MetALD are limited. This review offers practical guidance for health care professionals on how to integrate alcohol use into existing, recommended MASLD care pathways.